Benu Services

Development Services

Benu Biopharma utilizes a “Virtual” business model, with the oversight of a small cadre of highly skilled and experienced biotechnology managers, that enables early stage compounds or biologics to be moved into the _clinic and through clinical proof of principle expeditiously and efficiently.

Corporate Managerial Services

- Senior executive functions
- Strategic planning and analysis
- Technology and intellectual property assessments, portfolio triage and due diligence activities
- Pre-clinical- animal efficacy, pharmacology, toxicology, pharmacokinetic and ADME studies to cGLP and ICH standards
- Clinical – Phase 1 through Phase 3 in US, Europe and Canada
- Regulatory Affairs

Consulting Services

Benu BioPharma offers biotechnology _companies more than 60 years of combined experience in drug and biologic product_development, providing advice and experience during the crucial early stages of development. Benu Biopharma provides comprehensive product development, portfolio management and diligence services.

Early Phase General Strategic Services

- Technology evaluations
- Due diligence activities
- Market analyses
- Product development plans
- Business plans
- Scientific advisory panels
- Regulatory and product approval strategies

Product Specific Services

- Pre-clinical development programs
- Clinical development programs
- Regulatory affairs
- Manufacturing

News and Events

November 14, 2017

eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association
>> Read More

December 19, 2016

Capstone Therapeutics Announces Profound, Rapid LDL Cholesterol Reduction in AEM-28-14 Primate Study
>> Read More

Aug. 25, 2016

Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc.
>> Read More

Feb. 03, 2016

Capstone Therapeutics Announces Existing Shareholder Decision Not to Extend Exclusive due Diligence Period Other OTC_CAPS
>> Read More

Dec. 15, 2015

Capstone Therapeutics Announces Loan From Existing Shareholder for Exclusive Due Diligence Period Other OTC_CAPS
>> Read More

Oct. 14, 2015

Capstone Therapeutics Announces Allowance of U.S Patent for Treatment of Diabetes with Apo E Mimetic Peptides
>> Read More